Key Insights
Asia is no longer a regional autoimmune story. The report shows a market where commercial momentum and clinical acceleration are reinforcing each other, making Asia increasingly hard to ignore for pipeline strategy and partnering.
The headline shifts are clear:
- A bigger share of global value is moving to Asia: Potential deal value expanded at 20.7% CAGR (2016–2025), reaching $29bn in 2025, or 24% of global autoimmune deal value.
- The market has tilted toward partnering, not fundraising: Deal “quality” has increased, with a clear shift toward higher value licensing, and licensing agreements reaching nearly $20bn potential deal value in 2025.
- Clinical activity is speeding up across the region: Trial initiations rose sharply after China’s 2018 implied approval reform, with a 30-day IND fast track introduced in 2025, and trial growth since 2021 exceeding 20% across leading diseases, led by atopic dermatitis at 33.2% AAGR.
You May Also Be Interested In…
Learn More About Autoimmune
- The Most Comprehensive Way to Search the Autoimmune Drug Development Landscape: Unique search ontologies based on Autoimmune drug and trial characteristics
- Market Leading Approach to Autoimmune Preclinical & Clinical Data Curation: Manual curation of key Autoimmune research and development data points by Autoimmune research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Autoimmune company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.
Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.
This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.
We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!
